Mechanism of Action
TRHR Signaling
TRH activates TRH receptor 1 and 2 (TRHR1/2), which are Gq-coupled GPCRs. In the pituitary, TRHR1 activation drives IP3/DAG signaling, releasing intracellular calcium and activating PKC, which stimulates TSH and prolactin gene transcription and secretion. In the brain, TRH modulates serotonergic, dopaminergic, and cholinergic neurotransmission via TRHR expressed on neurons in limbic and motor regions.
CNS and Spinal Cord Actions
TRH is a potent analeptic: it reverses sedation from barbiturates, ethanol, and other CNS depressants in rodents. This effect is independent of the thyroid axis and involves direct neuronal excitation. TRH also protects spinal cord neurons from injury, promotes motor neuron survival, and has been tested (with mixed results) for spinal cord injury and ALS.
Research Summary
TRH Stimulation Test
Clinical/HistoricalThe TRH stimulation test (200-500 ug IV, measure TSH at 20-30 min) was historically used to assess thyroid axis function and diagnose secondary/tertiary hypothyroidism. With the advent of sensitive TSH assays, the TRH test is now rarely needed clinically, but remains diagnostically useful in select cases of pituitary or hypothalamic disease.
Spinal Cord Injury
Clinical ResearchBased on TRH neuroprotection in animal SCI models, clinical trials of TRH administration in acute SCI were conducted in the 1980s-90s. Early results suggested benefit; subsequent larger trials were inconsistent. TRH analogs with improved CNS penetration and stability (JTP-2942, taltirelin) are under investigation in Japan for ALS and SCI.
Depression and CNS Effects
Preclinical/ClinicalTRH and its stable analogs (taltirelin) have antidepressant and anti-suicidal effects in clinical studies. Rapid-acting antidepressant responses have been reported after IV TRH infusion, potentially via serotonergic and dopaminergic modulation. Taltirelin is approved in Japan for spinocerebellar degeneration.
Calculate your TRH (Thyrotropin-Releasing Hormone) dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| TRH stimulation test (pituitary) | 200-500 ug IV | Single dose (draw TSH at 0, 20, 60 min) | Intravenous |
| Antidepressant/CNS (research) | 0.5-2 mg IV infusion | Single or repeated infusions | Intravenous infusion |
| Spinal cord protection (rodent) | 2 mg/kg IV | Single or repeated doses post-injury | Intravenous |
Clinical use is primarily diagnostic. TRH analogs (taltirelin) are used therapeutically in Japan. Native TRH has a 2-5 min half-life, limiting therapeutic applications without continuous infusion or analog development.
Interactions
Safety Profile
Single-dose diagnostic TRH causes transient side effects: nausea, flushing, urge to urinate, and mild hypertension (typically < 5 minutes). Contraindicated in ischemic heart disease due to transient blood pressure changes. Rarely causes prolonged side effects. Chronic TRH analog use (taltirelin) shows good tolerability in Japanese clinical experience. Not WADA-listed.
References
- [1]Boler J, et al. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun. 1969;37(4):705-710.
- [2]Faden AI, et al. Thyrotropin-releasing hormone improves outcome following experimental spinal trauma in cats: dose-response and late treatment studies. Brain Res. 1983;273(1):167-174.
- [3]Callahan JF, Pavia MR. Thyrotropin-releasing hormone analogues: a review. Med Res Rev. 1992;12(6):579-620.